{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:43:57Z","timestamp":1793659437648,"version":"4.5.1"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ctrv.2022.102467","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T11:49:14Z","timestamp":1664970554000},"page":"102467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage"],"prefix":"10.1016","volume":"111","author":[{"given":"Gaia","family":"Giannone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna R.","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Earle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ayres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Pettaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain A.","family":"McNeish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2022.102467_b0005","doi-asserted-by":"crossref","unstructured":"Araldi RP, Sant\u2019Ana TA, M\u00f3dolo DG, De Melo TC, Spadacci-Morena DD, De Cassia Stocco R, et al. The human papillomavirus (HPV)-related cancer biology: an overview. Biomed Pharmacother 2018;106:1537\u201356.","DOI":"10.1016\/j.biopha.2018.06.149"},{"key":"10.1016\/j.ctrv.2022.102467_b0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bpobgyn.2020.02.009","article-title":"HPV vaccination and cancer prevention","volume":"65","author":"Athanasiou","year":"2020","journal-title":"Best Practice Res Clin Obstetrics Gynaecol"},{"key":"10.1016\/j.ctrv.2022.102467_b0015","unstructured":"Cancer IAfRo. Biological agents. International Agency for Research on Cancer 150 cours Albert Thomas, 69372 Lyon Cedex 08, France. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 20122012."},{"key":"10.1016\/j.ctrv.2022.102467_b0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2019.11.039","article-title":"Human papillomavirus vaccine against cervical cancer: Opportunity and challenge","volume":"471","author":"Wang","year":"2020","journal-title":"Cancer Lett"},{"issue":"24","key":"10.1016\/j.ctrv.2022.102467_b0025","doi-asserted-by":"crossref","first-page":"11585","DOI":"10.1158\/0008-5472.CAN-07-3007","article-title":"Role of Rb-dependent and Rb-independent functions of papillomavirus E7 oncogene in head and neck cancer","volume":"67","author":"Strati","year":"2007","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.ctrv.2022.102467_b0030","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.virol.2011.09.018","article-title":"Dominant role of HPV16 E7 in anal carcinogenesis","volume":"421","author":"Thomas","year":"2011","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102467_b0035","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102467_b0040","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/1471-2407-12-398","article-title":"HPV infection, anal intra-epithelial neoplasia (AIN) and anal cancer: current issues","volume":"12","author":"Stanley","year":"2012","journal-title":"BMC Cancer."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102467_b0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2468-1253(20)30304-6","article-title":"Anal cancer and precancerous lesions: a call for improvement","volume":"6","author":"Albuquerque","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2022.102467_b0050","unstructured":"SEER.cancer.gov. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/corp.html."},{"key":"10.1016\/j.ctrv.2022.102467_b0055","doi-asserted-by":"crossref","unstructured":"Deutsch F, Regina Bullen I, Nguyen K, Elliott M, Tran N. Current state of play for HPV-positive oropharyngeal cancers. Cancer treatment reviews: Cancer treatment reviews; 2022. p.102439.","DOI":"10.1016\/j.ctrv.2022.102439"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102467_b0060","doi-asserted-by":"crossref","first-page":"864","DOI":"10.20892\/j.issn.2095-3941.2020.0370","article-title":"Biological and clinical aspects of HPV-related cancers","volume":"17","author":"Anna Szymonowicz","year":"2020","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.ctrv.2022.102467_b0065","first-page":"1","article-title":"Penile cancer","volume":"7","author":"Thomas","year":"2021","journal-title":"Nat Rev Disease Primers"},{"issue":"9895","key":"10.1016\/j.ctrv.2022.102467_b0070","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(13)60022-7","article-title":"Human papillomavirus and cervical cancer","volume":"382","author":"Crosbie","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102467_b0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/aje\/kwn036","article-title":"Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis","volume":"168","author":"Koshiol","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ctrv.2022.102467_b0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pvr.2015.06.007","article-title":"Seroconversion following anal and genital HPV infection in men","volume":"1","author":"Giuliano","year":"2015","journal-title":"Papillomavirus Res."},{"issue":"3","key":"10.1016\/j.ctrv.2022.102467_b0085","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/cid\/cix797","article-title":"A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries","volume":"66","author":"Kjaer","year":"2018","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.ctrv.2022.102467_b0090","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S1473-3099(16)30120-7","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"16","author":"Wheeler","year":"2016","journal-title":"Lancet Infect. Dis."},{"issue":"9706","key":"10.1016\/j.ctrv.2022.102467_b0095","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years","volume":"374","author":"Romanowski","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102467_b0100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jnci\/djz074","article-title":"Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial","volume":"112","author":"Qiao","year":"2020","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctrv.2022.102467_b0105","unstructured":"Available from: https:\/\/en.walvax.com\/products\/products-list; 2022."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102467_b0110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.ctrv.2022.102467_b0115","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against Infection and Intraepithelial Neoplasia in Women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102467_b0120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ctrv.2022.102467_b0125","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102467_b0130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Mu\u00f1oz","year":"2010","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102467_b0135","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-050669","article-title":"Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial","volume":"11","author":"Lehtinen","year":"2021","journal-title":"BMJ Open."},{"issue":"14","key":"10.1016\/j.ctrv.2022.102467_b0140","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2022.102467_b0145","doi-asserted-by":"crossref","unstructured":"Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2018;2020(3).","DOI":"10.1002\/14651858.CD009069.pub3"},{"key":"10.1016\/j.ctrv.2022.102467_b0150","unstructured":"World Health Organization. 17 November 2020. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240014107."},{"issue":"11","key":"10.1016\/j.ctrv.2022.102467_b0155","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(21)00453-8","article-title":"Vaccine efficacy against persistent human papillomavirus (HPV) 16\/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study","volume":"22","author":"Basu","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctrv.2022.102467_b0160","article-title":"Dose-related effectiveness of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia: a Danish nationwide cohort study","author":"Verdoodt","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ctrv.2022.102467_b0165","doi-asserted-by":"crossref","unstructured":"Barnabas Ruanne V, Brown Elizabeth R, Onono Maricianah A, Bukusi Elizabeth A, Njoroge B, Winer Rachel L, et al. Efficacy of single-dose human papillomavirus vaccination among young African women. NEJM Evidence 2022;1(5):EVIDoa2100056.","DOI":"10.1056\/EVIDoa2100056"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102467_b0170","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ygyno.2013.05.033","article-title":"HPV vaccine cross-protection: Highlights on additional clinical benefit","volume":"130","author":"De Vincenzo","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102467_b0175","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malag\u00f3n","year":"2012","journal-title":"Lancet Infect Dis."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102467_b0180","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-0165-x","article-title":"Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6\/16\/18\/31\/33\/45\/52\/58 induced by bivalent and quadrivalent HPV vaccines","volume":"5","author":"Mariz","year":"2020","journal-title":"npj Vaccines"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102467_b0185","first-page":"505","article-title":"Cervical cancer prevention and control in women living with human immunodeficiency virus","volume":"71","author":"Castle","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2022.102467_b0190","first-page":"1","article-title":"Prevalence and distribution of human papillomavirus genotypes among women in Kinshasa, The Democratic Republic of the Congo","volume":"5","author":"Mutombo","year":"2019","journal-title":"J Global Oncol"},{"issue":"48","key":"10.1016\/j.ctrv.2022.102467_b0195","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1016\/j.vaccine.2013.09.032","article-title":"Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study","volume":"31","author":"Denny","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102467_b0200","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e3181de8d26","article-title":"Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old","volume":"55","author":"Levin","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102467_b0205","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1086\/656320","article-title":"Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men","volume":"202","author":"Wilkin","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ctrv.2022.102467_b0210","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD013479","article-title":"Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males","author":"Bergman","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"9447","key":"10.1016\/j.ctrv.2022.102467_b0215","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102467_b0220","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/ijc.26362","article-title":"Efficacy of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in women aged 15\u201325 years with and without serological evidence of previous exposure to HPV-16\/18","volume":"131","author":"Szarewski","year":"2012","journal-title":"Int J Cancer"},{"issue":"9580","key":"10.1016\/j.ctrv.2022.102467_b0225","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"issue":"9686","key":"10.1016\/j.ctrv.2022.102467_b0230","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102467_b0235","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1002\/ijc.31231","article-title":"Vaccination protects against invasive HPV-associated cancers","volume":"142","author":"Luostarinen","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2022.102467_b0240","article-title":"Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial","author":"Goldstone","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ctrv.2022.102467_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2020.106363","article-title":"Monitoring HPV vaccine impact on cervical disease: Status and future directions for the era of cervical cancer elimination","volume":"144","author":"Oliveira","year":"2021","journal-title":"Prev Med"},{"issue":"10316","key":"10.1016\/j.ctrv.2022.102467_b0250","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102467_b0255","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience","volume":"63","author":"Garland","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"10197","key":"10.1016\/j.ctrv.2022.102467_b0260","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102467_b0265","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/jnci\/djab080","article-title":"Real-world effectiveness of human papillomavirus vaccination against cervical cancer","volume":"113","author":"Kjaer","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2022.102467_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanwpc.2021.100251","article-title":"Genital warts trends in Australian and overseas-born people in Australia: a cross-sectional trend analysis to measure progress towards control and elimination","volume":"16","author":"Khawar","year":"2021","journal-title":"Lancet Regional Health - Western Pacific"},{"issue":"41","key":"10.1016\/j.ctrv.2022.102467_b0275","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737","article-title":"The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?","volume":"23","author":"Patel","year":"2018","journal-title":"Eurosurveillance"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102467_b0280","doi-asserted-by":"crossref","DOI":"10.1186\/s13027-017-0129-6","article-title":"Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe","volume":"12","author":"Hartwig","year":"2017","journal-title":"Infectious Agents Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102467_b0285","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-018-1098-3","article-title":"Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review","volume":"16","author":"Harder","year":"2018","journal-title":"BMC Med"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102467_b0290","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S1473-3099(20)30687-3","article-title":"Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study","volume":"21","author":"Chow","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ctrv.2022.102467_b0295","article-title":"Population trends and long-term outlook for oropharyngeal cancer","author":"Osazuwa-Peters","year":"2021","journal-title":"JAMA Otolaryngol-Head Neck Surgery"},{"key":"10.1016\/j.ctrv.2022.102467_b0300","doi-asserted-by":"crossref","unstructured":"Damgacioglu H, Sonawane K, Zhu Y, Li R, Balasubramanian BA, Lairson DR, et al. Oropharyngeal cancer incidence and mortality trends in all 50 states in the US, 2001-2017. JAMA Otolaryngol\u2013Head Neck Surg. 2021.","DOI":"10.1001\/jamaoto.2021.3567"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102467_b0305","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.2017.75.0141","article-title":"Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States","volume":"36","author":"Chaturvedi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102467_b0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068329","article-title":"Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica","volume":"8","author":"Herrero","year":"2013","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102467_b0315","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.2907","article-title":"Projected association of human papillomavirus vaccination with oropharynx cancer incidence in the US, 2020\u20132045","volume":"7","author":"Zhang","year":"2021","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.ctrv.2022.102467_b0320","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/21645515.2019.1662363","article-title":"Pregnancy outcomes after human papillomavirus vaccination in periconceptional period or during pregnancy: a systematic review and meta-analysis","volume":"16","author":"Wang","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ctrv.2022.102467_b0325","series-title":"Comprehensive cervical cancer control: a guide to essential practice","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.ctrv.2022.102467_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2020.106399","article-title":"HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010\u20132019","volume":"144","author":"Bruni","year":"2021","journal-title":"Prev Med"},{"key":"10.1016\/j.ctrv.2022.102467_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2021.106462","article-title":"A world without cervical cancer is within our reach","volume":"144","author":"Giuliano","year":"2021","journal-title":"Prev Med"},{"issue":"10224","key":"10.1016\/j.ctrv.2022.102467_b0340","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(20)30157-4","article-title":"Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Canfell","year":"2020","journal-title":"Lancet"},{"issue":"10224","key":"10.1016\/j.ctrv.2022.102467_b0345","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","article-title":"Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Brisson","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102467_b0350","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/infdis\/jiv368","article-title":"Human papillomavirus vaccination of boys and extended catch-up vaccination: effects on the resilience of programs","volume":"213","author":"Elfstr\u00f6m","year":"2016","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102467_b0355","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/ijc.31119","article-title":"Impact of gender-neutral or girls-only vaccination against human papillomavirus\u2014results of a community-randomized clinical trial (I)","volume":"142","author":"Lehtinen","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2022.102467_b0360","doi-asserted-by":"crossref","unstructured":"Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJLM, Berkhof J. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ 2015;350(may12 7):h2016-h.","DOI":"10.1136\/bmj.h2016"},{"key":"10.1016\/j.ctrv.2022.102467_b0365","unstructured":"Available from: https:\/\/www.europeancancer.org\/2-standard\/112-recommendations-on-vaccination-a-four-step-plan-for-eliminating-hpv-cancers-in-europe#:\u223c:text=By%202025%2C%20all%20European%20country,place%20in%20all%20European%20countries."},{"key":"10.1016\/j.ctrv.2022.102467_b0370","unstructured":"WHO. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/mi4a\/who-hpv-vaccine-global-market-study-april-2022.pdf?sfvrsn=6acb4c98_1&download=true 2022."},{"issue":"11","key":"10.1016\/j.ctrv.2022.102467_b0375","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/S1473-3099(20)30860-4","article-title":"Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis","volume":"21","author":"Drolet","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ctrv.2022.102467_b0380","unstructured":"recommendations Hv. 2021. Available from: https:\/\/www.cdc.gov\/vaccines\/vpd\/hpv\/hcp\/recommendations.html."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102467_b0385","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24\u201345 years of age","volume":"105","author":"Castellsagu\u00e9","year":"2011","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102467_b0390","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrclinonc.2015.146","article-title":"HPV-FASTER: broadening the scope for prevention of HPV-related cancer","volume":"13","author":"Bosch","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102467_b0395","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/07853890.2018.1426875","article-title":"On surmounting the barriers to HPV vaccination: we can do better","volume":"50","author":"Attia","year":"2018","journal-title":"Ann Med"},{"issue":"32","key":"10.1016\/j.ctrv.2022.102467_b0400","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.vaccine.2018.02.003","article-title":"Status of HPV vaccine introduction and barriers to country uptake","volume":"36","author":"Gallagher","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.ctrv.2022.102467_b0405","unstructured":"Available from: https:\/\/www.gavi.org\/types-support\/vaccine-support\/human-papillomavirus."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102467_b0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid2701.191364","article-title":"Impact of human papillomavirus vaccination, Rwanda and Bhutan","volume":"27","author":"Baussano","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102467_b0415","doi-asserted-by":"crossref","first-page":"e637","DOI":"10.1016\/S1470-2045(19)30531-5","article-title":"Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts","volume":"20","author":"Sankaranarayanan","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102467_b0420","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ypmed.2018.12.014","article-title":"Mode of HPV vaccination delivery and equity in vaccine uptake: a nationwide cohort study","volume":"120","author":"Wang","year":"2019","journal-title":"Prev Med"},{"key":"10.1016\/j.ctrv.2022.102467_b0425","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2019.04.032","article-title":"Human papillomavirus vaccination: the ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy","volume":"116","author":"Joura","year":"2019","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102467_b0430","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.vaccine.2013.11.070","article-title":"Literature review of HPV vaccine delivery strategies: Considerations for school- and non-school based immunization program","volume":"32","author":"Paul","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ctrv.2022.102467_b0435","unstructured":"Available from: https:\/\/www.cdc.gov\/mmwr\/volumes\/70\/wr\/mm7035a1.htm#:\u223c:text=National%20Vaccination%20Coverage,%25%20and%2089.3%25%20. 2022."},{"issue":"6","key":"10.1016\/j.ctrv.2022.102467_b0440","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1080\/21645515.2015.1129090","article-title":"Provider communication about HPV vaccination: a systematic review","volume":"12","author":"Gilkey","year":"2016","journal-title":"Hum Vaccines Immunother"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102467_b0445","doi-asserted-by":"crossref","first-page":"E74","DOI":"10.1503\/cmaj.140900","article-title":"Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study","volume":"187","author":"Smith","year":"2015","journal-title":"CMAJ"},{"issue":"10255","key":"10.1016\/j.ctrv.2022.102467_b0450","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0140-6736(20)31558-0","article-title":"Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study","volume":"396","author":"De Figueiredo","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102467_b0455","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-018-6316-6","article-title":"Achieving high uptake of human papillomavirus vaccination in Malaysia through school-based vaccination programme","volume":"18","author":"Muhamad","year":"2018","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ctrv.2022.102467_b0460","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/EDBK_239363","article-title":"The power of social media for HPV vaccination-not fake news!","volume":"39","author":"Teoh","year":"2019","journal-title":"Am Soc Clin Oncol Educational Book"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102467_b0465","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/bjc.2013.444","article-title":"Celebrities and screening: a measurable impact on high-grade cervical neoplasia diagnosis from the \u2018Jade Goody effect\u2019 in the UK","volume":"109","author":"Casey","year":"2013","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102467_b0470","doi-asserted-by":"crossref","DOI":"10.2196\/10244","article-title":"Discordance between human papillomavirus twitter images and disparities in human papillomavirus risk and disease in the United States: mixed-methods analysis","volume":"20","author":"Lama","year":"2018","journal-title":"J Med Internet Res"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102467_b0475","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3390\/jcm10051044","article-title":"RG1-VLP and other L2-based, broad-spectrum HPV vaccine candidates","volume":"10","author":"Huber","year":"2021","journal-title":"J Clin Med"},{"issue":"13","key":"10.1016\/j.ctrv.2022.102467_b0480","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00566-22","article-title":"RG2-VLP: a vaccine designed to broadly protect against anogenital and skin human papillomaviruses causing human cancer","volume":"96","author":"Olczak","year":"2022","journal-title":"J Virol"},{"key":"10.1016\/j.ctrv.2022.102467_b0485","doi-asserted-by":"crossref","unstructured":"Prem K, Choi YH, B\u00e9nard \u00c9, Burger EA, Hadley L, Laprise J-F, et al. Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis. 2021.","DOI":"10.1101\/2021.02.08.21251186"},{"key":"10.1016\/j.ctrv.2022.102467_b0490","unstructured":"https:\/\/www.who.int\/news\/item\/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer. 2022."},{"issue":"44","key":"10.1016\/j.ctrv.2022.102467_b0495","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1016\/j.vaccine.2021.09.033","article-title":"Research priorities to increase vaccination coverage in Europe (EU joint action on vaccination)","volume":"39","author":"Francis-Oliviero","year":"2021","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.ctrv.2022.102467_b0500","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1016\/j.vaccine.2020.04.032","article-title":"Using Facebook to increase coverage of HPV vaccination among Danish girls: an assessment of a Danish social media campaign","volume":"38","author":"Loft","year":"2020","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102467_b0505","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1080\/21645515.2021.1975449","article-title":"Promoting HPV vaccination on social media: interactive effects of threat, efficacy and social cues","volume":"17","author":"Chen","year":"2021","journal-title":"Hum Vaccines Immunother"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102467_b0510","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab011","article-title":"Human papillomavirus vaccination after COVID-19","volume":"5","author":"Toh","year":"2021","journal-title":"JNCI Cancer Spectrum"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102467_b0515","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jadohealth.2020.08.013","article-title":"Getting human papillomavirus vaccination back on track: protecting our national investment in human papillomavirus vaccination in the COVID-19 era","volume":"67","author":"Gilkey","year":"2020","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.ctrv.2022.102467_b0520","unstructured":"World Health Organization. 2021. Available from: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/fighting-infection-with-information."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:27:31Z","timestamp":1759656451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222001360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":104,"alternative-id":["S0305737222001360"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102467","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102467","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102467"}}